New Anti-Anginal Drugs: Ranolazine

Author(s): Chiara Cavallino, Manuela Facchini, Alessia Veia, Sara Bacchni, Andrea Rognoni, Francesco Rametta, Alessandro Lupi, Angelo S. Bongo.

Journal Name: Cardiovascular & Hematological Agents in Medicinal Chemistry

Volume 13 , Issue 1 , 2015

Become EABM
Become Reviewer

Abstract:

Chronic angina represents a condition that impairs quality of life and is associated with decreased life expectancy in the industrialized countries. Current therapies that reduce angina frequency include old drugs such as nitrates, β -blockers and calcium antagonists. Several new investigational drugs are being tested for the treatment of chronic angina. This review will focus on ranolazine, a drug approved by the US Food and Drug Administration (FDA) in 2006 for patients with chronic angina who continue to be symptomatic despite optimized therapies. The main molecular mechanism underlying ranolazine-mediated beneficial effects has been identified as inhibition of the late Na+ current during the action potential, which potentially improves oxygen consumption, diastolic dysfunction and coronary blood flow. The aim of this review is to update the evidence for ranolazine treatment in chronic angina and discuss its therapeutic perspectives based on the most recent clinical and experimental studies.

Keywords: Calcium antagonist, coronary artery disease, ranolazine, stable angina, β-blockers, nitrogen.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 13
ISSUE: 1
Year: 2015
Page: [14 - 20]
Pages: 7
DOI: 10.2174/1871525713666141219112841

Article Metrics

PDF: 42